Featured Research

from universities, journals, and other organizations

Better approach to treating deadly melanoma identified

Date:
December 19, 2012
Source:
Manchester University
Summary:
Scientists have identified a protein that appears to hold the key to creating more effective drug treatments for melanoma, one of the deadliest cancers.

Scientists at The University of Manchester have identified a protein that appears to hold the key to creating more effective drug treatments for melanoma, one of the deadliest cancers.

Researchers funded by Cancer Research UK have been looking at why new drugs called "MEK inhibitors," which are currently being tested in clinical trials, aren't as effective at killing cancer cells as they should be.

They discovered that MITF -- a protein that helps cells to produce pigment but also helps melanoma cells to grow and survive -- is able to provide cancer cells with a resistance to MEK inhibitors.

Dr Claudia Wellbrock and her team at the Wellcome Trust Centre for Cell-Matrix Research compared human melanoma cells that respond to the drug to cells that don't. They discovered that the cells that didn't respond to the drug contained higher levels of the protein SMURF2.

The researchers reduced the level of SMURF2 in the melanoma cancer cells and then treated the tumour with the MEK inhibitor. They found a 100 fold increase in the sensitivity of the cells to the drug. It appears that removing SMURF2 radically decreases the level of MITF in melanoma cells, making the MEK inhibitor a lot more powerful.

Using mice with tumours the team found that over a three week period there was a substantial decrease in tumour growth when the removal of SMURF2 was used in combination with MEK inhibitors.

Dr Wellbrock says: "Much of cancer research is now focussed on finding new drug combinations. It's recognised that cancers frequently find new ways to combat even the most novel and highly efficient drug treatments, so we are now focussing on targeting the mechanisms that allow the cancer cells to overcome the drug effects. We're very excited about the potential for this new approach that has proved to be so effective in our experiments."

One of the drawbacks of the MEK inhibitor drug is that it targets all cells. MEK (MAP/ERK kinase protein) is present in all cells but cancer cells have overactive MEK. This means the drug must be used in small doses and for a lengthy period to avoid harming healthy cells. By reducing SMURF2 to increase the drug's effectiveness smaller doses could be given over a shorter time period, reducing the level of toxicity in healthy cells.

Dr Wellbrock says: "If we can reduce the toxicity to all cells it will mean cancer treatments are less harmful to patients. It's vital that we improve the treatments for melanoma which is the fifth most common cancer in the UK. By the time many people are diagnosed with melanoma the cancer has already started to spread and advanced tumours can be highly resistant to conventional cancer treatments. The development of resistance to new drugs has also been a major drawback. If we can identify more potent and less toxic drug combinations to tackle melanoma then we could save thousands of lives."

This study was funded in part by Cancer Research UK and the results have been published in the Journal of the National Cancer Institute.

Talking about the research Dr Julie Sharp from the charity said: "Recently there have been some really exciting developments in treating melanoma -- but new approaches that tackle the problem of resistance are still needed. This type of research will be a key focus of the planned new Manchester Cancer Research Centre which will bring together a wide range of research expertise to revolutionise cancer treatment."

The next step for Dr Wellbrock will be to find a drug that can reduce the activity of SMURF2 in cancer cells. The Manchester research team are now screening drug libraries for an existing drug that may already be approved for use for a different illness.

It's hoped that identifying a drug to use in combination with MEK inhibitors will provide a much more powerful and ultimately more successful approach to treating melanoma.


Story Source:

The above story is based on materials provided by Manchester University. Note: Materials may be edited for content and length.


Journal Reference:

  1. M. P. Smith, J. Ferguson, I. Arozarena, R. Hayward, R. Marais, A. Chapman, A. Hurlstone, C. Wellbrock. Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma. JNCI Journal of the National Cancer Institute, 2012; DOI: 10.1093/jnci/djs471

Cite This Page:

Manchester University. "Better approach to treating deadly melanoma identified." ScienceDaily. ScienceDaily, 19 December 2012. <www.sciencedaily.com/releases/2012/12/121219082813.htm>.
Manchester University. (2012, December 19). Better approach to treating deadly melanoma identified. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2012/12/121219082813.htm
Manchester University. "Better approach to treating deadly melanoma identified." ScienceDaily. www.sciencedaily.com/releases/2012/12/121219082813.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins